Table 1.
Clinical characteristics of the development cohort and validation cohort.
| Characteristicsa | Development (N = 827) | Validation (N = 414) | P-value |
|---|---|---|---|
| Donor age (years) | 47.3 (±9.8) | 47.4 (±9.7) | 0.88 |
| Donor sex (Male) | 33.00% | 31.50% | 0.72 |
| Donor eGFR | 109.4 ± 13.7 | 115.6 ± 17.5 | 0.63 |
| Recipient age (years) | 33.1 (±8.3) | 32.7 (±8.7) | 0.43 |
| Recipient sex (Male) | 71.70% | 71.90% | 0.95 |
| Recipient BMI, Kg/m2 | 21.5 (±3.5) | 21.8 (±18) | 0.72 |
| Cold ischemic time (h) | 2.5 (±0.9) | 2.5 (±0.9) | 0.88 |
| DGF | 1.10% | 1.50% | 0.48 |
| Induction therapy | 0.46 | ||
| No | 33.90% | 31.60% | |
| ATG | 11.95% | 10.60% | |
| IL-2 R antibody | 54.20% | 57.90% | |
| HLA mismatches | 0.11 | ||
| ≤3 mismatch | 11.50% | 15.00% | |
| >3 mismatch | 88.50% | 85.00% | |
| Pre-transplant PRA >20% | 2.90% | 2.90% | 0.95 |
| Duration of dialysis, months | 13.4 (±14.8) | 13.4 (±15.8) | 0.94 |
| Transplant year | 0.56 | ||
| 2007–2012 | 266 | 140 | |
| 2013–2017 | 561 | 274 |
ATG, antithymocyte globulin; BMI, body mass index; eGFR, estimated glomerular filtration rate; DGF, delayed graft function; HLA, human leukocyte antigen; PRA, panel reactive antibody.
a
Continuous data are presented as mean ± standard deviation (SD), and categorical data as percentage of the total, unless otherwise noted.